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Background: Musculoskeletal problems are common, accounting for up to 30 % of general practitioner (GP)
consultations and are a major cause of chronic disability worldwide. Demand for health care for musculoskeletal
conditions is likely to continue to rise given the ageing population and the increasing impact of these common
painful conditions. Physiotherapists are well equipped to deliver evidence-based management for these conditions.
Direct access allows patients to access physiotherapy without seeing their GP or another referring practitioner first;
however, for most patients in the UK, access to National Health Service physiotherapy is controlled through GP referral.
Methods/Design: The aim of this pilot, pragmatic, cluster trial is to assess the feasibility of a future large trial to
compare the clinical and cost-effectiveness of the additional offer of direct access to physiotherapy versus continuing
with usual GP-led primary care alone for adults with common musculoskeletal problems. The pilot will focus on
process outcomes to assess feasibility, although performance of the likely outcomes of a main trial will also be
assessed. This is a two-arm parallel, cluster RCT where GP practices are the units of randomisation (the clusters), yet
data are collected from individual patients with musculoskeletal problems (the participants). A direct access service will
be set up in the participating physiotherapy service to provide the option of direct access to patients of the
intervention arm practices. Inclusion criteria are broad to reflect the ‘real-world’ operation of an NHS physiotherapy
direct access service for patients with musculoskeletal pain. Data collection will be through patient self-reported
questionnaires at baseline, 2, 6 and 12 months and medical record review.
Discussion: No previous trials have been conducted into direct access to physiotherapy for patients with
musculoskeletal problems. The strengths of the STEMS pilot trial are its size, the length of follow-up, and collection of
process, clinical and cost outcomes to fully inform a future main trial to meet calls to provide robust trial evidence of
the impact on clinical outcomes, work loss and costs to provide clinicians and service funders with the high quality trial
data they need to guide decisions on the best models of care.
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Musculoskeletal problems are common and costly and
increase with age. Musculoskeletal conditions account
for up to 30 % of general practitioner (GP) consultations
[1], and yet it is estimated that only between 30–40 % of
individuals with musculoskeletal problems consult their
GP [2–4]. The Global Burden of Disease Study shows
that musculoskeletal conditions are a major cause of
chronic disability worldwide and have increased mark-
edly in the last decade [5]. Given the ageing population
and the increasing impact of these common painful con-
ditions, the demand for musculoskeletal healthcare is set
to rise and health care delivery systems will need to de-
velop a ‘coherent policy for dealing with musculoskeletal
disorders’ [5]. Best evidence for many of these musculo-
skeletal conditions recommends treatments such as ad-
vice, education, exercise, manual therapy and acupuncture
[1, 6, 7]. Such treatments are cost-effective [8] and are
those that professionals such as physiotherapists are
equipped to deliver. Early physiotherapy intervention for
musculoskeletal problems reduces sick leave and helps
prevent acute problems becoming chronic [1, 9–12].
However, for most patients in the UK, access to National
Health Service (NHS) physiotherapy is controlled through
GP referral.
Direct access to physiotherapy is a system of access in
which ‘patients are able to refer themselves to a physio-
therapist directly without having to see anyone else first or
without being told to refer themselves by a health profes-
sional’ [13]. Although direct access is well established in
private practice in the UK and in other countries including
Australia, the Netherlands, some states within the USA
and in Scotland [14–17], uptake in the NHS in England
has been very limited. Funders of physiotherapy services
express concerns about creating excessive demand and as-
sociated costs and where direct access services have been
established at least one in England has been stopped due
to funding being withdrawn [18].
To date, evidence about direct access to physiotherapy
comes from observational studies only. These have sug-
gested that direct access may reduce GP workload [19]
with estimates of a 20 % reduction in multiple GP consul-
tations [20]. An evaluation in the Netherlands reported
that in the first 12 months of direct access, patients refer-
ring themselves accounted for 22–28 % of all physiother-
apy referrals [14, 21]. Reported patient benefits of direct
access are greater freedom of choice and improved access
to musculoskeletal care [13, 14, 19, 22], since direct access
allows the patient to opt for physiotherapy when they are
in most need. There are also some suggested cost-
benefits, with GP referral costing £133 an episode and an
episode of care through direct access costing £100 [23].
A global review of direct access to physiotherapy has
identified professional legislation, the medical profession,politicians and policy makers as both barriers to and fa-
cilitators of direct access [24]. A European-focused re-
view of direct access services concluded that clinicians,
managers and service funders need high quality trial
data on both clinical and cost-effectiveness to guide de-
cisions on the best models of care [25]. In addition, an
independent evaluation of the observational UK Depart-
ment of Health pilots of direct access to physiotherapy
[13] concluded that robust evidence of the impact on
clinical outcomes, work loss and costs are lacking due to
important flaws in observational study designs and that
a randomized controlled trial (RCT) comparing areas
that do and do not offer direct access is required to pro-
vide robust evidence about direct access [26].
The most appropriate design for a RCT to evaluate
direct access is a non-inferiority cluster RCT that com-
pares the clinical and cost-effectiveness of the additional
offer of direct access to physiotherapy versus continuing
with usual GP-led care alone for patients with musculo-
skeletal conditions in primary care. However, given that
this involves developing a new direct access service, it is
important to conduct feasibility and pilot work first in
order to fully inform a future main trial.
Overall aim
The overall aim of the STEMS pilot trial is to assess the
feasibility of a future large trial to compare the clinical
and cost-effectiveness of the additional offer of direct
access to physiotherapy versus continuing with usual
GP-led primary care alone for adults with common mus-
culoskeletal problems.
Objectives
The objectives of the STEMS pilot trial include both
process and research objectives. Analysis of the process
objectives will enable the feasibility of a larger cluster RCT
to be assessed. They focus on the feasibility of working
with general practices and physiotherapy services to de-
velop and set up a direct access to physiotherapy service,
the acceptability of direct access and the ability to both re-
cruit and retain participants in the research evaluation.
Process objectives
1. To assess the number of practices approached and
agreeing to take part (baseline) and the engagement
of GP practices and physiotherapy services to stay in
the pilot trial through follow-up (12 months)
2. To develop and test approaches to market a new
direct access service in ways that ensure a sufficient
proportion (at least 20 %) of patients access
physiotherapy through self-referral to make a main
trial feasible (assessed through referral methods as
physiotherapy service)
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physiotherapy direct access service that can respond
to demand and avoid increases in waiting times or
staffing levels (monitored throughout the
recruitment period)
4. To estimate participant recruitment rates in both
control and intervention practices (assessed at end
of recruitment)
5. To explore any evidence of selection bias in
participants recruited to the research evaluation
from the control and intervention practices
(assessed through participant characteristics at
baseline)
6. To estimate retention of participants in the research
evaluation at each follow-up time-point across both
control and intervention practices
Research objectives
The pilot trial will also provide a useful test of outcome
data collection methods, including key clinical out-
comes, and provide information on the likely changes in
these outcomes in the control and intervention groups.
Whilst a main trial will provide the definitive test of the
difference between trial groups on these clinical out-
comes, the pilot has the following research objectives:
1. To investigate likely changes in the primary clinical
outcome measure (physical health measured using
the SF36v2 Physical Component Summary)
2. To investigate likely changes in secondary outcome
measures (overall perceived change, mental health,
pain self-efficacy, quality of life, understanding of the
condition, experience of care and convenience and
accessibility of service)
3. To provide an early estimate of the costs, both
healthcare and societal costs, in both intervention
and control groups
4. To explore the use of willingness to pay (WTP)
methodology to capture the strength of patient
preferences for direct access to NHS physiotherapy
5. To confirm the parameters needed for a realistic
sample size calculation for a future main cluster RCT
Methods
Design
The design is a pilot, pragmatic, cluster RCT in general
practice and physiotherapy services. The most appropri-
ate trial design is a simple, two-arm parallel, cluster
RCT where GP practices are the units of randomisation
(the clusters), yet data are collected from individual pa-
tients with musculoskeletal problems (the participants).
This design overcomes the problem of contamination
between arms and the problems associated with indi-
vidually consenting and randomising patients to a trialtesting service-level changes. A main trial would employ a
non-inferiority design as it will be essential that the inter-
vention is as least as good as usual GP-led care in terms of
patients’ clinical outcomes (physical health measured
using the SF36v2 Physical Component Summary).
A repeated measures design will be adopted, whereby
participants will complete the questionnaires at baseline,
2, 6 and 12 months. Each participant’s involvement in
the trial is for 12 months, during which time they will all
have access to usual GP-led primary care. No analysis of
clinical outcomes will be undertaken until the 12-month
follow-up time-point.
Setting and clusters
The setting is primary care in England for adults with
musculoskeletal problems (GP practices and linked NHS
physiotherapy services). GP practices are the unit of ran-
domisation, and thus, patients follow the care pathways
to which the practice is randomised. In this pilot, RCT
practices will be stratified only on practice size, but in a
main trial, practices would also ideally be stratified by
index of deprivation. Randomisation of GP practices will
be undertaken by an independent statistician. GP prac-
tices will be randomised to one of two arms, either to
continue with usual GP-led primary care for musculo-
skeletal patients with the addition of the offer of a self-
referral physiotherapy pathway (intervention group) or
to continue with usual GP-led primary care alone (usual
care control group). Practices will be randomised accord-
ing to a computer-generated random numbers stratified
by the practice size (small or large) in the ratio 1:1. In a
main study, we would plan to further stratify by practice
setting and area level deprivation (through minimisation)
in order to ensure balance in key practice characteristics
in each arm of the trial.
GP practices are eligible to take part if they meet the
following criteria: they are within the Vale Royal Clinical
Commissioning Group area of Cheshire and the Clinical
Research Network (CRN); they are a group practice, cur-
rently referring musculoskeletal patients to NHS physio-
therapy services; they do not currently offer direct
access to physiotherapy; and they are willing to test dir-
ect access. The balance between scientific considerations
and the need for consent is a known issue for cluster tri-
als [27]. Informed consent for practices to participate
will be provided by the senior GP partner in each prac-
tice acting as ‘guardian’ for patients in their care. Pa-
tients will follow the care to which their practice is
randomised with identical patient information for both
arms providing general information about the study,
explaining that their local musculoskeletal services are
being evaluated using patient self-reported clinical out-
comes and medical record review. Individual patients
will therefore be able to opt out of data collection.
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The inclusion criteria have been designed to be as broad
as possible to reflect the ‘real-world’ operation of an NHS
physiotherapy direct access service for patients with mus-
culoskeletal pain.
Inclusion criteria are all adults consulting participating
GP practices or physiotherapy services with musculoskel-
etal problems (for either their first consultation for a new
episode of musculoskeletal pain or a reconsultation).
Exclusion criteria are: under 18 years old at the time
of consultation; consulting with non-musculoskeletal
problems; unable to provide their own consent to the
research evaluation; undergoing palliative care; severe
learning disabilities; housebound or in nursing home ac-
commodation; and unable to communicate in English
(although all potential participants will be offered the
opportunity to telephone a research nurse, blinded to
practice allocation, for help in completing the paperwork).
Participant identification and recruitment
Following randomisation of GP practices, potentially eli-
gible participants will be identified through one of three
methods.
Method 1: Patients consulting GP practices with a
musculoskeletal problem will have a musculoskeletal
Read code1 (entered by GPs or nurse practitioners) en-
tered into their computerised medical record. A member
of the GP practice team, or CRN staff, will download the
details of patients with these Read codes twice weekly
checking for exclusion criteria and then forward these
details to a CRN administrator. GPs will be able to ex-
clude any patients they perceive as being particularly
vulnerable and unsuitable to approach for involvement
in research by using a dedicated exclusion code set up
for the study.
Method 2: In addition, for those GP practices rando-
mised to also offer direct access to physiotherapy, pa-
tients who self-refer to physiotherapy will be identified
when they forward a completed self-referral form to the
physiotherapy service or telephone the physiotherapy ad-
ministrator for help in completing a form. As in method
1 the details of identified patients will be forwarded to a
CRN administrator.
Method 3: Patients referred by GPs or practice nurses
to the physiotherapy service, but not identified in
method 1 due to an absence of an appropriate Read code
in the computerised medical records, will be identified
from the physiotherapy administration database. A
physiotherapy administrator will download the details of
all patients referred from the participating GP practices
twice weekly and forward these details to a CRN admin-
istrator. Duplication checks will ensure that eligible pa-
tients are not invited to take part in the research more
than once.All eligible patients will be mailed a STEMS study
pack (letter of invitation, participant information leaflet
(see Additional file 1), consent form, baseline question-
naire and pre-paid return envelope). Participants will
not be individually consented to randomisation, rather
participants in both arms of the trial will be asked to
give written consent to take part in a study investigating
musculoskeletal problems and local health services, con-
sisting of the baseline and follow-up questionnaires (at
2, 6 and 12 months) and to allow the research team ac-
cess to their medical records to review healthcare use
for their musculoskeletal problem. Patients interested in
participating will be offered the option of telephoning a
research nurse, blinded to practice allocation, who will
answer any questions and support those who need it to
complete the consent form and questionnaire over the
phone. Participants who consent to participation will re-
turn the completed questionnaire and consent form to
the research centre, and the research team will then have
access to their personal identification details. Partici-
pants completing the consent form but having missing
data at baseline on the primary outcome measure (the
SF36v2), such that a Physical Component Summary
score cannot be calculated, will be contacted by telephone
to collect the missing data. At each data collection time-
point (baseline, 2, 6 and 12 months), non-responders
will be mailed a postcard reminder 2 weeks after mail-
ing of the trial study pack and a repeat study pack
2 weeks after the reminder postcard. At 6- and 12-
month follow-up, non-responders will subsequently be
mailed a very brief minimum data questionnaire, con-
sisting of the SF-36v2 and the single Global Assessment
of Change question only. Telephone collection of mini-
mum data will be attempted for the remaining non-
responders.
This method of recruitment has been used successfully
in previous studies. Our processes ensure that all eligible
patients will be identified, recruited through postal study
packs (with telephone support where needed) with iden-
tical information about the evaluation study given to
those in both arms of the trial [27]. Participants’ GPs will
be notified of their consent to participate in the research
evaluation. Participating general practices will be sup-
ported to assist with identification of potentially eligible
participants for the STEMS pilot trial through small
practice payments to reimburse their time for screening
patient lists. The physiotherapy service will be supported
to participate through financial reimbursement for the
time taken from service delivery for participation in the
training programme. Participants will not receive any
payments or other incentives to take part in the STEMS
pilot trial or to return baseline or follow-up question-
naires. A flowchart illustrating the STEMS pilot trial is
shown in Fig. 1.
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Allocation concealment for participating GPs and phys-
iotherapists is not possible, and therefore, to prevent re-
cruitment bias, neither of these groups of clinicians will
be involved in recruiting participants into the research
evaluation. Instead eligible participants will be identified
from electronic GP medical records and from the
physiotherapy service database, conducted by CRN staff.
We will follow the CONSORT guidelines for both clus-
ter trials and non-inferiority trials [28, 29]. In an ideal
world, the comparison would be all patients who have a
musculoskeletal problem in the participating practices
during the study period, whether or not they attend their
GP and/or physiotherapy service, but clearly this is not
possible. Therefore, all patients who consult their GP
practice (control arm) will be compared with all patients
who consult their GP or physiotherapy service (interven-
tion arm) with a musculoskeletal condition. Patients
who directly access physiotherapy may be different in
important ways to those who consult their GP, which is
a limitation of the design. Therefore, in the pilot trial,
we will investigate whether the number of consulters (to
GPs only in the control arm and to either GPs orFig. 1 Flow chart of the STEMS pilot cluster randomised trialphysiotherapists in the intervention arm) that have been
identified in each arm are similar, whether there appears
to be any differential uptake to the research evaluation
in the two arms and whether the baseline characteristics
of participants in each arm are similar.
Both primary and secondary outcomes are based on
self-report postal questionnaires; therefore, no investiga-
tor bias will be introduced at assessment. The research
nurses involved in helping patients to complete ques-
tionnaires and minimum data collection will be based in
the Clinical Research Network, not in participating prac-
tices, and will be kept blind to practice allocation. Suc-
cess of blinding will be recorded on the Minimum Data
Collection form. In addition, the trial statistician under-
taking the analysis will also be blind to practice alloca-
tion. Using validated outcome measures for self-report
will guard against measurement error. Quality control
including data entry, coding, security, storage and man-
agement will be performed according to the Standard
Operating Procedures of the Keele Clinical Trials Unit.
A random 10 % of the participants’ data entered will be
compared with the paper versions to check data entry
accuracy. Data accuracy will be audited and accuracy
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implementing standardised reminder procedures and
minimal data collection for non-responders. Participants
will be free to withdraw from the research at any time
without having to give any explanation. Where possible,
we will collect information about the reasons for with-
drawal. All records will be kept confidential and data sets
for each participant will be identified by the patient’s par-
ticipant number. Analysis will be performed on an
intention-to-treat (ITT) basis using the full set of available
data (mixed model and multiple imputation of missing
data). Patients self-referring or being GP-referred receive
equitable treatment, for example, in the length of wait to
first physiotherapy contact once they are logged on the
physiotherapy administration system. The physiotherapists
participating in the trial will provide physiotherapy care to
patients from both arms of the trial (initiated from trad-
itional GP referral in the control arm versus from both
traditional GP referral and patient self-referral in the inter-
vention arm). As this trial is investigating the addition of
direct access to physiotherapy, the physiotherapy care pro-
vided will be determined by clinical need and assessment
findings and will therefore be consistent with routine prac-
tice and not differ for patients in different arms of the trial.
Description of intervention and control arms
Control practices: In GP practices allocated to the con-
trol arm patients will continue to be managed according
to usual GP-led care. This normally consists of a patient
consulting their GP and receiving advice and treatment
(often medication but we expect around 20–25 % to be
referred to physiotherapy, or for a diagnostic test or
other treatment service). For some patients, it may mean
being triaged by a practice nurse and managed with ad-
vice and/or referral to physiotherapy or other services.
Usual GP-led care therefore includes all of these path-
ways in participating GP practices but will not include
the offer of direct access to physiotherapy. No additional
information on physiotherapy services will be dissemi-
nated by the research team to GP practices delivering
usual care. Regular contact with, and feedback to, the
control practices through CRN staff, a GP research fa-
cilitator and from the PI and study team will help ensure
smooth trial operationalisation.
Intervention practices: In practices allocated to the
intervention arm patients will continue to be able to ac-
cess care via usual GP-led care pathways (as described
above) in addition to direct access to physiotherapy for
musculoskeletal patients. Direct access will allow adults
with musculoskeletal problems to refer themselves to
the physiotherapy service. Those opting for direct access
to physiotherapy will complete a self-referral form,
which will be available at their GP practice or, where
possible, online. The self-referral form will includequestions about ‘red flag’ symptoms, indicative of sus-
pected serious pathology that would require urgent med-
ical investigation, with advice to patients to contact their
GP if one or more of these symptoms are present. Sub-
mitted self-referral forms will be reviewed by a senior
physiotherapist who will identify, based on existing
physiotherapy service criteria, whether the referral is ap-
propriate and whether classed as urgent or routine. Ur-
gent cases will be offered the next available appointment
whereas routine cases will join all other routine patients
on a waiting list for the physiotherapy service and be
seen in order of receipt of referral. In cases where the re-
ferral is considered inappropriate for physiotherapy
management, the patient will be contacted by the
physiotherapy service and signposted to the most appro-
priate practitioner or service. Direct access to physio-
therapy will be actively marketed in the intervention
practices to ensure that all registered patients are aware
of this option [30]. This will start eight weeks prior to
participant recruitment to the research evaluation and
continue until patient recruitment to the trial has fin-
ished. Marketing will include communications with
practice staff (clinical and administrative teams), practice
posters, rolling presentations in practice waiting areas
(where possible), patient flyers and self-referral forms in
practices. In order to best ensure that all adults in the
practice become aware of the availability of direct access,
an information letter and direct access flyer will be
mailed to all registered adult patients at each interven-
tion practice. A phased approach to the marketing of the
new service is planned, over 8 weeks, so that demand
for physiotherapy through direct access can be moni-
tored. The posters, flyers and forms will clearly explain
how patients can directly access the service. The physio-
therapy administrator will input patients’ data into the
trial registration database and be responsible for arran-
ging face-to-face physiotherapy appointments at con-
venient times and dates following prioritisation of the
referrals by senior physiotherapists in the service. Even
with the offer of direct access, we anticipate that many
patients will opt to consult their GP as usual. Therefore,
in the intervention practices, patients may consult their
practice and be referred to physiotherapy, either by
written referral or be recommended to access physio-
therapy by GPs or nurse practitioners (GP or nurse rec-
ommended self-referral) or choose to directly access
physiotherapy without contacting their GP practice (true
self-referral). Each patient’s pathway will be recorded.
Support for physiotherapists providing the direct access
service
Although physiotherapists are autonomous practitioners
on qualification, additional education and development
needs of physiotherapists have been identified as part of
Table 1 STEMS pilot trial process measures
Engagement of GP practices and PT services
Physiotherapy site recruitment rate to participate in STEMS study
GP Practice recruitment rate to participate in STEMS study
Research evaluation
Recruitment rate to the research evaluation—all adults with
musculoskeletal conditions
Recruitment rate to the research evaluation—‘true self-referral’a patients
Recruitment rate to the research evaluation—‘recommended
self-referral’b patients
Retention rates to research evaluation at 2, 6 and 12 months follow-up
GP practice characteristics
Number of GPs and nurse practitioners per practice
Number of patients and number of adults registered at practice
GP consultation rates for adults with musculoskeletal conditions
(before and during study)
Physiotherapy team characteristics
Number of physiotherapists working in the physiotherapy service
(in total and STEMS trained)
Seniority of physiotherapists in the physiotherapy service
(in total and STEMS trained)
Physiotherapy service
Physiotherapy service GP referral rate (before and during study)
Physiotherapy service ‘true self-referral’a rate
Physiotherapy service ‘recommended self-referral’b rate
Non-attendance rates at physiotherapy site for GP referrals
(before and during study) and for self-referrals during study
Number of physiotherapy consultations for GP referrals, ‘true self-referral’
and ‘recommended self-referral’ patients in the intervention practices
Number of self-referring patients deemed unsuitable at each stage in
the direct access pathway
Onward referral rate from physiotherapy (to GP, other services) for GP
referrals, ‘true self-referral’ and ‘recommended self-referral’
Physiotherapy waiting time (month-by-month) from 12 months prior to
introduction of direct access to end of study
Number of patient complaints about direct access at physiotherapy site
Monitoring of safety
Number of cases of missed serious pathology in patients directly
accessing physiotherapy
Number of adverse events in GP-referred, ‘true self-referral’
‘recommended self-referral’
aThose who are prompted by their GP or practice nurse to access
physiotherapy care
bThose who directly access physiotherapy care without prompting by their GP
or practice nurse
Bishop et al. Pilot and Feasibility Studies  (2015) 1:26 Page 7 of 15the work-up of the pilot trial and a training programme is
planned to address these. The brief training programme
will include the following content: prevalence and identifi-
cation of red flags, serious pathology and medical mas-
queraders, review of common over-the-counter and
prescribed medications for musculoskeletal pain patients,
the provision of occupational/work advice to patients and
information about the practicalities of the trial, including
delivery of the trial protocols and identification of any ser-
ious pathologies or serious adverse events. Continuing
support of physiotherapists delivering the direct access
service will take the form of a mentoring programme pro-
vided by the lead musculoskeletal physiotherapist in the
team and another senior physiotherapist who has experi-
ence of providing direct access services. The physiother-
apy service leads will also agree pathways for patients
using direct access with suspected serious pathology
who are in need of medical attention, or who may re-
quire a fit note or a prescription from their GP. Approxi-
mately 18 physiotherapists will participate in the training
programme, half of whom will initially provide the new
direct access physiotherapy service and the remainder will
be able to provide cover as needed throughout the dur-
ation of the trial, for example for holiday periods.
Outcome measures
Process outcomes: Process outcomes will determine if a
future main trial is possible and desirable. Anonymised
process outcome data will be collected from GP records
and physiotherapy administration databases and self-
referral forms. Health service process outcomes include
the proportion of patients not referred to physiotherapy
services, those referred to physiotherapy and the num-
ber of patients directly accessing physiotherapy in the
intervention practices, proportion of ‘recommended
self-referral’ and ‘true self-referral’ in the direct access
pathway, waiting times for treatment (time from logging
of referral to first physiotherapy appointment), number of
GP and NHS physiotherapy consultations for musculo-
skeletal problems and non-attended physiotherapy ap-
pointments (DNA rates). Research process outcomes
include estimation of recruitment rates, exploration of evi-
dence of selection bias and follow-up rates at each time-
point with differences in the control and intervention
practices explored to identify sources of bias. A summary
of the process measures is shown in Table 1.
Clinical outcomes: Data collection will include the col-
lection of clinical and cost data through patient self-
report questionnaires at baseline and 2, 6 and 12 months
follow-up. The primary clinical outcome is physical
health measured using the SF36v2 Physical Component
Summary. A summary of the clinical outcomes and
other measures included in each questionnaire is shown
in Table 2.Adverse events
The occurrence of adverse events from all interventions
will be monitored and assessed using case report forms,
contact with the trial coordinator, physiotherapist report,
and follow-up questionnaires. However, as the interven-
tion is the introduction of a direct access pathway and
the treatments received will be the same as in usual
Table 2 STEMS pilot trial questionnaire measures
Domains Description
Baseline 2 months 6 months 12 months
Primary outcome measure
Physical function SF36v2 physical component summary http://www.sf-36.org/ ✓ ✓ ✓ ✓
Secondary outcome measures
Overall change in condition Global assessment of change since baseline—single question ✘ ✓ ✓ ✓
Mental health SF36v2 mental component summary http://www.sf-36.org/ ✓ ✓ ✓ ✓
Quality of life EuroQol EQ-5D-5 L www.euroqol.org ✓ ✓ ✓ ✓
Self-efficacy Pain self-efficacy questionnaire (PSEQ) [31] ✓ ✓ ✓ ✓
Understanding of condition General practice assessment questionnaire enablement subscale [32] ✓ ✓ ✓ ✘
Experience of consultations General practice assessment questionnaire communication [32] ✓ ✓ ✓ ✘
Accessibility of services Single question ✘ ✓ ✓ ✘
Satisfaction with services Single question ✘ ✓ ✓ ✘
Baseline measures
Demographics Gender, date of birth, ethnicity, education, health literacy, employment
status, socio-economic status (recent paid job title, housing)
✓ ✘ ✘ ✘
Baseline risk of persistent
problems
STarT Musc tool (draft tool developed at Keele University to identify
patients’ risk of persistent pain and disability)
✓ ✘ ✘ ✘
Pain location Body manikin ✓ ✘ ✘ ✘
Pain duration Single question about duration of pain ✓ ✘ ✘ ✘
Comorbidities Single question ✓ ✘ ✘ ✘
Economic outcomes
Further health care utilisation Consultations, investigations, procedures, admissions,
over-the-counter medications
✘ ✘ ✓ ✓
Work absence Single question ✓ ✓ ✓ ✓
Presenteeism Single work performance question ✓ ✓ ✓ ✓
Willingness to pay Three willingness to pay questions ✘ ✘ ✘ ✓
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apists and GPs will report any serious adverse event
(SAE) experienced by a trial participant immediately to
the trial chief investigator that may possibly be related to
either the interventions or the trial procedures. The
chief investigator will assess whether the event was re-
lated to or resulted from any of the STEMS study trial
interventions or procedures. Any SAE considered to be
related to the trial procedures or interventions will be
reported to the main Research Ethics Committee by the
chief investigator within 15 days of her becoming aware
of the event. In addition, all such events will be reported
to the trial sponsor, Trial Steering Committee and Data
Monitoring Committee.
Safety of direct access to physiotherapy
Any serious or significant pathologies that would require
urgent medical assessment missed by physiotherapists in
patients who directly access care will be reported. Phys-
iotherapists and GPs will be asked to report any cases
they become aware of. In addition, a systematic searchof the GP medical record for participants who consent
to medical record review and who directly access physio-
therapy care will be undertaken to identify any possible
cases of missed serious or significant pathology. The
number of missed serious pathologies will be described
only for participants directly accessing physiotherapy.
Sample size
As this is a pilot trial, a formal sample size calculation
has not been carried out. Using Keele’s Consultation in
Primary Care Archive (CiPCA) database of GP practices
and symptom and diagnostic Read codes, 25 % of the
population in an average-sized GP practice (5000 pa-
tients) consults at least once per year with a musculo-
skeletal problem (1250 patients or 100 patients per
month). Given the trial exclusions, we anticipate at least
80 % of consulters to be eligible (80 patients per month
per practice), 50 % to respond to the invitation to take
part in the research evaluation, provide consent and
complete a baseline questionnaire (40 patients per
month per practice). With four practices recruiting for
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at baseline and 80 % follow-up (n = 768).
Analysis
Since this is a pilot trial, the analyses will focus on de-
scribing the key process measures in order to decide if a
main trial is feasible and desirable, in addition to finalis-
ing the sample size for a future main trial.
Determine engagement of GP practices and the
physiotherapy service
The number of GP practices and physiotherapy services
that have agreed to participate in the trial will be re-
corded and presented as a proportion of the number of
eligible practices approached. Information will be pre-
sented that summarises GP practice characteristics (full-
time equivalent of GP staff, number of patients and
number of adults registered at practice and GP consult-
ation rates for musculoskeletal patients before and dur-
ing pilot trial recruitment as well as the physiotherapy
team characteristics (full-time equivalent staff and their
clinical grades).
Feasibility of study recruitment and retention
The number of participants identified and recruited
using each recruitment method will be reported, along
with the number of participants followed up at each
time-point. Withdrawals (and where possible, reasons
for withdrawals) will be reported. A priori, we have de-
fined a success criterion of 40 % of the total number of
participants invited to be recruited to the research evalu-
ation. Whilst a retention rate of 100 % would be ideal,
we will consider a rate of 70 % at 6 months follow-up
satisfactory. We will provide the point estimate of the
proportion and its 95 % confidence interval (CI). Differ-
ence in recruitment uptake rate and follow-up rates at
each time-point will be compared between the interven-
tion and control arms.
Feasibility of direct access
An audit of the feasibility of offering direct access will
be conducted using anonymised data. This will include
reporting the number of participants who are referred to
physiotherapy by their GP, those who are ‘recommended
self-referrals’ (prompted by their GP or practice nurse to
refer) and those who are ‘true self-referrals’ and the wait-
ing time to the first physiotherapy appointment. Figures
will be presented month-by-month for patients using
direct access as well as the overall totals. The proportion
of patients directly accessing care (true and recom-
mended self-referrals) compared to all referrals received
at the physiotherapy site will be calculated to check the
success of marketing the direct access service. The aim
is to ensure that a minimum of 20 % of the totalphysiotherapy caseload during the pilot trial, from prac-
tices randomised to the intervention arm, is through dir-
ect access. In order to assess the feasibility of establishing
a direct access service that can respond to demand, de-
scriptive measures of the total number of referrals re-
ceived from participating practices and staffing levels in
the participating physiotherapy department will be used to
establish how the physiotherapy service responds to de-
mand through waiting time for first physiotherapy ap-
pointment. The source by which patients, who access care
directly, become aware of the direct access service will be
presented and compared in order to establish which
methods (GP advised, poster, individual mailing, heard
from a friend and other methods) are most successful in
marketing the service.
Evidence of selection bias
Since this is a pilot trial with only four clusters rando-
mised, it is likely that there will be some imbalance be-
tween participants in each of the treatment arms on one
or more baseline characteristics. Baseline comparisons
will be carried out to detect any substantial differences
between participants recruited from the control and
intervention arms. This will be done by scrutinising the
baseline table for any serious imbalances in observable
baseline variables and the trends of the imbalance if any.
The recruitment rates will also be estimated and com-
pared between the control and intervention arms. We
will examine the size of any imbalances and decide if
there is evidence of systematic selection bias in the types
of patients being recruited in control versus intervention
arms. Any systematic imbalance in the sense that one
arm is consistently favoured by the imbalances may not
reflect chance alone and may suggest selection bias.
Explore generalisability of the sample
Anonymised data on key baseline characteristics (age, gen-
der and index of multiple deprivation (from post-codes)) of
those who are invited but who do not participate will be
compared with those who do participate. Key baseline
characteristics will be compared between those participants
followed up and those lost to follow-up at each time-point.
Key characteristics of the participants recruited using each
recruitment method will be reported. Delays in return of
questionnaires (>35 days from initial mailing date) will also
be compared between the two arms.
Analyses of clinical outcomes
Analyses will be conducted for the clinical outcomes, but
this will be treated as exploratory and will be mainly de-
scriptive. A baseline table (descriptive statistics and fre-
quencies) will compare the demographic and clinical
characteristics (gender, age, education, employment status,
pain interference with performance at work, type of
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PCS) and mental health (SF-36v2 MCS), pain location,
physical function, pain duration, baseline risk of persistent
problems, comorbidities, pain self-efficacy, understanding
of the condition, experience of care and convenience and
accessibility of service) between the two arms. Since the
baseline assessment for the clinical characteristics will be
completed, for many patients, after their initial consult-
ation about their musculoskeletal problem, there could be
implications on evaluation and interpretation of these
measures as they may not be ‘true baseline’ but rather
possible ‘outcomes’ at the first time-point. All continuous
variables will be summarised using mean, standard devi-
ation, median and interquartile range as appropriate. The
frequency and percentages of observed levels will be re-
ported for all categorical measures.
As this is a pilot trial, no emphasis will be put on the
p values for any inferential statistical tests conducted. A
mixed effect model, which allows all available data at all
the four time-points to be used and account for missing
data and clustering effect, will be used to estimate a
two-sided 95 % CI to show a credible range for the true
difference in the SF-36v2 PCS subscale between inter-
vention and the control arms. The model will be ad-
justed for key patient-level baseline characteristics (age,
area level deprivation and widespread pain (from mani-
kin data)) and a random effect for the GP practices and
will include a treatment-by-time interaction to obtain
the estimates of treatment effect (and 95% CI) at each
follow-up visit (2, 6 and 12 months). Analyses of the sec-
ondary outcomes will be performed similarly.
Further analysis will descriptively compare the base-
line characteristics and key clinical outcomes between
the participants referred to physiotherapy in the control
practices with participants self-referring in the inter-
vention practices. We will also compare the self-
referrers with those that do not self-refer within the
intervention group.
The pilot data will provide information on the parame-
ters needed for a realistic sample size calculation (mean,
standard deviation and treatment effects of the primary
outcome for the two arms) for a future, main cluster
RCT. The intra-cluster correlation (ICC) will be calcu-
lated and compared with the estimates from previous
large primary-care-based trials. However, as we only
have 4 GP practices, we expect the estimated ICC to be
unreliable given the likely wide confidence intervals.
The non-inferiority margin will not be calculated from
the pilot data as previous research in musculoskeletal
disorders has estimated a minimal clinically important
difference (MCID) from 2 to 4 points for the SF-36v2
Physical Component Summary (PCS) subscale which
will be used to inform the non-inferiority margin of any
future main trial [33–36].Missing outcome data
Since the primary outcome measure, physical health
measured using the SF-36v2 PCS involves scoring indi-
vidual items, we do not expect all returned question-
naires to have every item on the SF-36 completed. Based
on the recommendation in the scoring manual [33], a
scale score should be calculated if a respondent answers
at least 50 % of the items in a scale. Missing data will be
estimated by the average score, across completed items
in the same scale for that respondent. If more than 50 %
of the items in a scale are left blank, the imputation al-
gorithm identifies the scale as ‘not computable’ and so
the respondent is considered to have missing data for
the SF-36v2 component scales.
In order to explore the extent and patterns of missing
outcome data, we will report the proportion of missing
values per item, proportion of participants who complete
all items on the questionnaire and the proportion of re-
spondents who answer at least 50 % of the items in a
scale. The proportion of missing data will also be re-
ported for the other key outcomes and compared be-
tween the participants from intervention and control
practices. The characteristics of those lost to follow-up
will also be compared with those who remain in the trial
through follow-up.
Safety of direct access
Any possible cases of missed serious or significant path-
ology will be discussed within the study team. For any
patient where there is evidence to suggest the physio-
therapist failed to correctly identify this pathology when
the patient directly accessed physiotherapy care and
medical intervention was delayed will be reported.
Health economic analysis
The economic analysis will be exploratory, with the aim to
inform the design of a full cost-utility analysis alongside a
future main trial. A cost-consequence analysis will be re-
ported, describing all the important results relating to costs
and consequences for direct access to physiotherapy and
usual care arms of the trial. Results will be presented from
a health service perspective and a broader societal perspec-
tive taking into account patient-incurred costs and prod-
uctivity losses. An exploratory willingness to pay (WTP)
study [37] will also be conducted to assess the use of this
methodology to measure broader benefits of direct access.
Data on costs will be sought from all participants and
from a broad perspective, taking into account healthcare,
patient and societal costs. Healthcare resource used will be
collected using self-completed questionnaires at 6 and
12 months, with a recall period of 6 months in each. Ques-
tions will ask patients to recall GP consultations, visits to
healthcare professionals, outpatient appointments, investi-
gations or treatments and inpatient stays related to the
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between NHS and private practice visits. Resource used
for the direct access pathway will be directly recorded and
costs attached, staff time (taking into account any in-
creased referrals to physiotherapy), materials (posters,
flyers, referral forms) and training sessions. GP medical
record review of all participants will provide data on rele-
vant prescribed medications for all musculoskeletal prob-
lems. In addition, information on costs borne by the
patient (e.g. over-the-counter medicines, devices) will be
collected via the self-complete questionnaires. Productiv-
ity costs will take into account both absenteeism and pres-
enteeism and will utilise self-report data on employment
status, occupation and time off work and reduced prod-
uctivity at work (presenteeism). As this is a pilot trial, the
suitability of questions for collecting cost data directly
from patients can be assessed, in order to ensure effective
resource use and that cost data collection systems are
established for a larger trial.
All patients will be asked to complete the 5-level version
of the EuroQoL-5D (EQ-5D) questionnaire at baseline,
6 months and 12 months in order for the quality-adjusted
life years (QALYs) over the 12-month time period to be
calculated for each participant. The QALYs combine infor-
mation on health-related quality of life and survival.
Resource use will be multiplied by unit costs obtained
from standard sources (NHS Reference Costs, British
National Formulary, Unit Costs of Health and Social Care)
and healthcare providers. Due to the lack of nationally
representative unit cost estimates for private healthcare,
this care will be costed as the NHS equivalent in the base
case. Patient reported costs for over-the-counter treat-
ments will be used. Productivity costs will be calculated
using data collected on employment status at every time-
point and days off work due to their musculoskeletal
problem. For those in paid employment, information on
occupation and the nature of their employment (full time
or part time) will be requested. The average wage for each
respondent will be identified using UK Standard Occupa-
tional Classification coding and annual earnings data for
each job type. The analysis will use the human capital ap-
proach, and the self-reported days of absence will be
multiplied by the respondent-specific wage rate. The hu-
man capital approach assumes that the value of lost work
is equal to the amount of resources an individual would
have been paid to do that work and values productivity
losses as a result of morbidity (or mortality) by measuring
time lost from work and multiplying this with the gross
wage of the person. Responses to the EQ-5D question-
naire at baseline and 6 and 12 months will be used to cal-
culate QALYs for each participant using the area under
the curve method.
As this is a pilot trial this will be an exploratory ana-
lysis, with the aim to inform the cost data collection andanalysis of a future main larger trial. We will test our
methods of collecting cost data, from patient question-
naires and medical record reviews and assess the com-
pleteness of the data collected. A cost-consequence
analysis will be reported, describing all the important re-
sults relating to costs and consequences. Analyses will
be mainly descriptive, and all costs and outcomes will be
summarised using means and 95 % confidence intervals.
The data for costs are likely to have a skewed distribu-
tion; therefore, the plan is to explore the nature of the
distribution of costs. If the data is not normally distrib-
uted, a non-parametric comparison of means (e.g. boot-
strapping) will be undertaken.
The base case cost analysis will adopt a NHS and per-
sonal social services (PSS) perspective. A broader costing
perspective will be considered in a sensitivity analysis, tak-
ing into account NHS/PSS costs, patients’ personal ex-
penditure and costs associated with work loss. The
robustness of the results will be explored using sensitivity
analysis and will explore uncertainties in the trial based
data and any assumptions made in the base case analysis.
Nested willingness to pay analysis Exploratory work
using a willingness to pay (WTP) approach that fits
within a cost-benefit analysis framework will also be
conducted in this pilot trial. Cost-benefit analysis is
ideally placed for the evaluation of interventions where
the benefits may be non-health related. The approach is
one way of measuring how valuable a service is and how
much (in monetary terms) participants would be willing
to give up in order to receive it. The hypothetical nature
of the question is highlighted in the information given to
participants. The WTP study questionnaire will be sent
to all participants at 12 months. The main WTP ques-
tion contains presenting the participant with a range of
monetary values in a table from £0 to £350 and asks par-
ticipants what is the maximum amount of money they
would be willing to pay to have direct access to a physio-
therapy service. A space is provided for them to explain
the reasons for their answer, and there are further ques-
tions asking if they would use a direct access service if
available and their annual household income.
Firstly, the pilot study will test the completion rate of
the WTP questions and whether WTP can be measured
in this context. This does not aim to obtain definitive
WTP findings but to explore the feasibility of the
method for use in a future main trial. Descriptive statis-
tics for willingness to pay values will be presented in
both trial arms, including the proportion of protest zero
responses. ‘Protest zeros’ occur when participants report
a zero WTP even though they value the service (in con-
trast to reporting a zero WTP if they do not value the
service) and are usually due to refusal to engage with the
WTP questions. All reasons for responses will be coded.
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to explore the relationship between stated WTP and par-
ticipant characteristics, using WTP values as the dependent
variable and variables such as trial arm, age, gender, health
status and income as independent variables.
Trial organisation and monitoring
The STEMS pilot trial is sponsored by Keele University.
The day-to-day operation of the trial will be overseen by a
Trial Management Group (led by AB), in line with the
Standard Operating Procedures of the Keele Clinical
Trials Unit. The Trial Management Group will meet
monthly and AB will meet more frequently with the study
coordinator. The trial will be monitored by an independ-
ent Trial Steering Committee (TSC) chaired by Professor
Tracey Howe, who will meet approximately twice a year
timed to coincide with key milestones, such as approval of
the protocol, approval of the statistical analysis plan and
interpretation of results. The TSC is made up of individ-
uals with expertise in musculoskeletal research, delivery of
care in general practice and lay members with musculo-
skeletal pain. An independent Data Monitoring Commit-
tee (DMC) monitors all trials conducted at the Research
Institute for Primary Care and Health Sciences. Having
reviewed the protocol and in view of the feasibility and
pilot nature of the STEMS pilot trial, the DMC (chaired
by Dr Janine Gray) proposed that monitoring of this study
remains the responsibility of the TSC. During the pilot
trial period no interim analyses are planned.
Dissemination
Results from the STEMS pilot study will be disseminated
through oral and poster presentations at conferences
along with publications in peer review journals and
other media. A report to the funder is a requirement of
funding and will be submitted at the end of the study.
Results will also be disseminated to participating general
practices and the physiotherapy service through face-to-
face meetings and/or electronic methods, depending on
preference. Results will be made available on the Re-
search Institute’s website and dissemination to partici-
pants will be coordinated in liaison with the Patient and
Public Involvement coordinator. Keele University CTU
has established data sharing arrangements to support
joint publications and other research collaborations.
Data confidentiality and archiving
The transportation of electronic sensitive data originating
from NHS sources, such as contact details or medical re-
cords, will be conducted in accordance with the guidelines
provided by NHS National Information Governance
Board (NIGB). Data collected as part of the medical rec-
ord review of consenting participants will be recorded on
NHS compatible encrypted laptop computers and thentransferred to university computers. Any transfer of per-
sonal information between CRN staff and GP practice or
physiotherapy service administrators will be transferred
using NHS email accounts. Paper records kept for re-
search purposes will include hard copies of the completed
questionnaires with signed consent forms and case report
forms (CRFs). Consent forms will contain names and ad-
dress but will be stored in a secure environment separate
from patient data. The contact details of consenting par-
ticipants will be required for mailing the follow-up ques-
tionnaires for this study. These contact details will be
stored on a separate database to their questionnaire re-
sponses and clinical data, linked by their unique ID num-
ber. All trial-related information will be stored securely at
the Research Institute for Primary Care and Health Sci-
ences at Keele University. Coded identification numbers
will be used to anonymise data with the data and the link-
ing code stored in separate locations, under password pro-
tection. Access to the data will be to the small number of
individuals necessary for quality control, audit and ana-
lysis. The final trial dataset will be accessed by the statisti-
cian (RO), the trial principal investigator (AB) and chief
investigator (NEF). We will publish and communicate the
pilot trial results regardless of the outcome of the trial.
Data from the STEMS pilot trial will be archived and
made available for future, secondary analysis and data
pooling purposes from the Research Institute for Primary
Care and Health Sciences at Keele University.Ethical review and trial registration
The STEMS pilot trial received research ethical approval
from NRES Committee North West—Preston in February
2013 (REC reference, 13/NW/0053), and site-specific ap-
provals have been received from the appropriate local re-
search and development offices. The trial is being
conducted in accordance with the ethical principles in the
Declaration of Helsinki and good practice guidelines on
the proper conduct of research. The STEMS pilot trial is
registered at Current Controlled Trials ISRCTN23378642.Results and discussion
The STEMS pilot trial will investigate the feasibility of
a future large trial to compare the clinical and cost-
effectiveness of the additional offer of direct access to
physiotherapy versus continuing with usual GP-led pri-
mary care alone for adults with common musculoskel-
etal problems. It is essential that changes to service
provision and delivery are supported by research evi-
dence and arguable that research about how to improve
the delivery of health care is just as important in im-
proving the health of patients with musculoskeletal
conditions as the testing of new drugs or therapeutic
approaches.
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has been limited to observational studies with the inherent
limitations of observational designs. No previous trials
have been conducted into direct access to physiotherapy
for patients with musculoskeletal problems and this pilot
trial will inform a main trial to fill this evidence gap and
meet the calls to provide robust trial evidence of the im-
pact on clinical outcomes, work loss and costs in a trial
comparing areas that do and do not offer direct access
[26] and to provide clinicians and service commissioners
with the high quality trial data they need to guide deci-
sions on the best models of care [25]. Direct access will be
deemed to be the preferred model if it is not inferior in
terms of patients’ physical health (on the SF-36v2
PCS—the main trial primary outcome) and is associ-
ated with benefits such as shorter waiting times, greater
satisfaction, improved work outcomes and greater cost-
effectiveness. Direct access may prove to be more cost-
effective if it reduces other health service consultations
and prescriptions, or improves quality of life or less
cost-effective if it involves additional physiotherapy
consultations with no reduction in GP consultations or
prescriptions or improvements in quality of life
The strengths of the STEMS pilot trial are its size, the
length of follow-up and collection of process, clinical and
cost outcomes to fully inform a future main trial. In
addition, marketing of the direct access service at GP
practice level will avoid contamination between arms but
will ensure that all registered adult patients are aware of
the direct access service. This will enable sufficient partici-
pants to directly access physiotherapy care during the
pilot trial to allow planned analyses. The care pathway to
physiotherapy in the intervention practices will be set up
to mimic closely what would happen if direct access were
routinely available. Although patients in the intervention
arm may choose to access physiotherapy directly without
ever contacting their general practice about their muscu-
loskeletal condition (true self-referrers), some patients will
contact their practice and may be advised that they can
self-refer to physiotherapy (recommended self-referrers).
The facility for GPs to send a written referral in the trad-
itional manner also continues as this may be particularly
suitable for some patients e.g. the frail elderly or those
with very complex problems.
Design considerations and limitations
We acknowledge that a limitation of the trial design is
recruiting patients in the control arm from GP practices
and in the intervention arm from GP practices and the
physiotherapy service. In an ideal design, we would com-
pare all patients who have a musculoskeletal problem
registered with participating practices during the study
period, whether or not they attend their GP and/or
physiotherapy service but clearly this is not possible.Other trial designs were considered, but these would
have led to greater differences in patients recruited to
the two arms of the trial. We will therefore make consid-
erable efforts to identify any evidence of selection and
recruitment bias between the arms of the pilot trial, al-
though we acknowledge that patients may differ on
other unknown factors.
It is possible that over time, as patients become accus-
tomed to direct access, their expectations and service
use may change. Clinical outcomes are unlikely to
change beyond 12-month follow-ups, but costs and ben-
efits may change as direct access becomes established
within a community. Therefore, this pilot trial includes
follow-up to 12 months as longer follow-up would be
expensive within the context of a trial.
This pilot aims to inform a main trial with a non-
inferiority design as the addition of a direct access to
physiotherapy pathway is not anticipated to be superior in
terms of patients’ clinical outcomes. However, a range of
secondary outcomes is included that in a main trial will
provide important information for patients, health care
practitioners and commissioners if clinical non-inferiority
is demonstrated. Previous work suggests an effect size of
0.2 to 0.6 as a minimum clinically important difference,
and we would thus, anticipate specifying a difference be-
tween groups of 0.2 as the threshold for the purposes of
demonstrating non-inferiority in a main trial.
Conclusions
This pilot cluster randomised control trial will provide
valuable information to inform a future future large trial
to compare the clinical and cost-effectiveness of the add-
itional offer of direct access to physiotherapy versus con-
tinuing with usual GP-led primary care alone for adults
with common musculoskeletal problems
Endnotes
1Read codes are the standard diagnostic codes used in
general practice in the UK
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